| Literature DB >> 22801363 |
Zhihong Tong1, Fang Yu, Zhonghua Liu, Haidong Liang.
Abstract
Ischemia-reperfusion (IR) can lead to serious tissue oxidative injury in animals. ShuJinHuoXue tablet (SJHXT) is a Chinese Traditional Medicine which can relax the muscles and stimulate the blood circulation and has been used as a clinical medicine. In the present study, we investigated the effects of SJHXT pretreatment on oxidative injury using an animal model of acute limb IR. Results showed that SJHXT pre-treatment (200, 300 and 400 mg/kg/day) markedly reduced serum endothelin-1 (ET-1), thromboxane B2 (TXB₂) levels and thromboxane B2/6-keto- prostaglandin F1α (TXB₂/6-Keto-PGF(1α)), wet weight/dried weight (W/D) ratio, myeloperoxidase (MPO), creatine kinase (CK), lactate dehydrogenase (LDH) activities, and increased serum nitric oxide (NO), 6-Keto-PGF(1α) levels and NO/ET-1 ratio in the IR+SJHXT groups. In addition, the SJHXT pre-treatment (200, 300 and 400 mg/kg/day) markedly reduced skeletal muscle Ca²⁺, malondialdehyde (MDA) levels, increased Na⁺-K⁺-ATPase, Ca²⁺-Mg²⁺-ATPase, superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities. Our results suggest that SJHXT pre-treatment may improve skeletal muscle blood vessel microcirculation, decrease skeletal muscle oxidative injury and enhance antioxidant enzymes activities in IR animals.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22801363 PMCID: PMC6268584 DOI: 10.3390/molecules17078494
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Effect of SJHXT on serum NO, ET-1, TXB2, 6-Keto-PGF1α levels, NO/ET-1 ratio and TXB2/6-Keto-PGF1α ratio in control and experimental groups.
| Group | NO | ET-1 | NO/ET-1 | TXB2
| 6-Keto-PGF1α
| TXB2/ |
|---|---|---|---|---|---|---|
| NC | 31.67 ± | 79.53 ± | 0.39 ± | 201.43 ± | 659.03 ± | 0.316 ± |
| IR | 50.82 ± | 275.83 ± | 0.18 ± | 517.39 ± | 871.62 ± | 0.594 ± |
| IR+SJHXT (200 mg/kg/day) | 59.09 ± | 227.09 ± | 0.26 ± | 487.27 ± | 968.26 ± | 0.503 ± |
| IR+SJHXT (300 mg/kg/day) | 66.48 ± | 197.53 ± | 0.34 ± | 451.38 ± | 1083.44 ± | 0.416 ± |
| IR+SJHXT (400 mg/kg/day) | 71.24 ± | 152.69 ± | 0.47 ± | 406.14 ± | 1192.49 ± | 0.341 ± |
b p <0.01, compared with NC group; c p < 0.05, d p < 0.01, compared with IR group; NC: normal control.
Effect of SJHXT on serum CK and LDH activities.
| Group | CK (μkat/L) | LDH (μkat/L) |
|---|---|---|
| NC | 93.06 ± 11.76 | 6.37 ± 0.77 |
| IR | 424.57 ± 52.87 b | 22.81 ± 2.41 b |
| IR+SJHXT (200 mg/kg/day) | 328.06 ± 47.18 d | 16.77 ± 2.05 d |
| IR+SJHXT (300 mg/kg/day) | 247.11 ± 36.01 d | 11.59 ± 1.31 d |
| IR+SJHXT (400 mg/kg/day) | 169.03 ± 18.09 d | 8.04 ± 0.92 d |
b p < 0.01, compared with NC group; d p < 0.01, compared with IR group.
Effect of SJHXT on serum MPO activity and W/D ratio.
| Group | MPO (μkat/L) | W/D |
|---|---|---|
| NC | 1.46 ± 0.18 | 5.01 ± 0.48 |
| IR | 4.39 ± 0.51 b | 6.94 ± 0.66 b |
| IR+SJHXT (200 mg/kg/day) | 3.88 ± 0.42 c | 6.43 ± 0.59 |
| IR+SJHXT (300 mg/kg/day) | 3.05 ± 0.29 d | 5.92 ± 0.55 c |
| IR+SJHXT (400 mg/kg/day) | 2.41 ± 0.22 d | 5.61 ± 0.48 c |
b p < 0.05, compared with NC group; c p < 0.05, d p < 0.05, compared with IR group.
Effect of SJHXT on skeletal muscle Ca2+ level, Na+-K+-ATPase and Ca2+-Mg2+-ATPase activities.
| Group | Ca2+
| Na+-K+-ATPase | Ca2+-Mg2+-ATPase |
|---|---|---|---|
| NC | 0.062 ± 0.007 | 2.38 ± 0.27 | 2.57 ± 0.31 |
| IR | 0.191 ± 0.013 b | 1.27 ± 0.14 b | 1.39 ± 0.15 b |
| IR+SJHXT (200 mg/kg/day) | 0.145 ± 0.011 c | 1.61 ± 0.19 | 1.75 ± 0.19 c |
| IR+SJHXT (300 mg/kg/day) | 0.107 ± 0.012 d | 1.93 ± 0.21 c | 2.28 ± 0.25 d |
| IR+SJHXT (400 mg/kg/day) | 0.082 ± 0.007 d | 2.22 ± 0.24 d | 2.49 ± 0.26 d |
b p < 0.05, compared with NC group; c p < 0.05, d p < 0.05, compared with IR group.
Effect of SJHXT on skeletal muscle MDA level, SOD, CAT and GSH-Px activities.
| Group | MDA (nmol/mg protein) | SOD (U/mg protein) | CAT (U/mg protein) | GSH-Px (U/mg protein) |
|---|---|---|---|---|
| NC | 3.16 ± 0.34 | 304.7 ± 34.15 | 68.31 ± 7.16 | 73.09 ± 6.88 |
| IR | 7.92 ± 0.68 b | 168.3 ± 18.59 b | 35.05 ± 4.03 b | 30.61 ± 3.71 b |
| IR+SJHXT (200 mg/kg/day) | 6.24 ± 0.66 d | 199.4 ± 22.11 d | 47.41 ± 5.12 d | 48.92 ± 5.05 d |
| IR+SJHXT (300 mg/kg/day) | 5.02 ± 0.57 d | 264.8 ± 30.08 d | 57.07 ± 6.06 d | 60.51 ± 7.82 d |
| IR+SJHXT (400 mg/kg/day) | 4.28 ± 0.51 d | 290.4 ± 31.49 d | 66.17 ± 7.29 d | 79.03 ± 6.79 d |
b p < 0.05, compared with NC group; d p < 0.05, compared with IR group.
Figure 1H&E staining A: NC; B: IR; C: IR+SJHXT (200 mg/kg/day); D: IR+SJHXT (300 mg/kg/day); E: IR+SJHXT (400 mg/kg/day).